Xenon Q2 Loss Wider Than Expected, Pipeline Development in Focus
XENE's wider Q2 loss highlights its push toward late-stage epilepsy, depression, and bipolar disorder studies with azetukalner.
Xenon to Report Q2 2025 Financial Results on August 11, 2025
VANCOUVER, British Columbia and BOSTON, Aug. 04, 2025 ( GLOBE NEWSWIRE ) -- Xenon Pharmaceuticals Inc. ( Nasdaq: XENE ) , a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced it will ...
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
VANCOUVER, British Columbia and BOSTON, Aug. 01, 2025 ( GLOBE NEWSWIRE ) -- Xenon Pharmaceuticals Inc. ( Nasdaq: XENE ) , a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced equity ...
Xenon Joins the Russell 3000® and Russell 2000® Indexes
VANCOUVER, British Columbia and BOSTON, June 27, 2025 ( GLOBE NEWSWIRE ) -- Xenon Pharmaceuticals Inc. ( Nasdaq: XENE ) , a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced that ...
Xenon Announces Appointment of Darren Cline as Chief Commercial Officer
Mr. Cline brings extensive commercial expertise to lead the transition of Xenon to a commercial-stage company with the anticipated launch of azetukalner across three potential indications Mr. Cline brings extensive commercial expertise to lead the transition of Xenon to a commercial-stage ...
Xenon Pharmaceuticals ( XENE ) Up 8.7% Since Last Earnings Report: Can It Continue?
Xenon Pharmaceuticals (XENE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
VANCOUVER, British Columbia and BOSTON, May 30, 2025 ( GLOBE NEWSWIRE ) -- Xenon Pharmaceuticals Inc. ( Nasdaq: XENE ) , a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced equity ...
Crude Oil Gains 3%; US Inflation Eases In April - Affimed ( NASDAQ:AFMD ) , Halozyme Therapeutics ( NASDAQ:HALO )
U.S. stocks traded mixed midway through trading, with the Dow Jones index falling around 200 points on Tuesday. The Dow traded down 0.49% to 42,203.63 while the NASDAQ gained 1.74% to 19,033.50. The S&P 500 also rose, gaining, 0.86% to 5,894.52. Information technology shares jumped by 2.3% on ...
Xenon Q1 Loss Narrower Than Expected, Pipeline Development in Focus
XENE incurs narrower-than-estimated first-quarter 2025 loss. Studies on lead candidate, azetukalner, in epilepsy and MDD are progressing well.
This Waste Connections Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Republic Services ( NYSE:RSG ) , Praxis Precision Medicine ( NASDAQ:PRAX )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Seaport Global analyst John Mazzoni initiated coverage on Waste Management, Inc.
Wall Street Analysts See a 48.15% Upside in Xenon Pharmaceuticals ( XENE ) : Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 48.2% in Xenon Pharmaceuticals (XENE). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the ...
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
VANCOUVER, British Columbia and BOSTON, May 02, 2025 ( GLOBE NEWSWIRE ) -- Xenon Pharmaceuticals Inc. ( Nasdaq: XENE ) , a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced equity ...
Xenon to Showcase Long-Term 36-Month Azetukalner Data at AAN 2025
VANCOUVER, British Columbia and BOSTON, April 04, 2025 ( GLOBE NEWSWIRE ) -- Xenon Pharmaceuticals Inc. ( Nasdaq: XENE ) , a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced ...
Xenon Q4 Loss Narrower Than Expected, Pipeline Development in Focus
XENE reports a narrower-than-expected fourth-quarter 2024 loss. Its development programs for azetukalner in epilepsy and MDD are progressing well.
Xenon Outlines Key Corporate Milestone Opportunities for 2025 - Xenon Pharmaceuticals ( NASDAQ:XENE )
- Topline data from the first Phase 3 FOS study anticipated in H2 2025 representing major milestone in support of NDA filing and potential launch of azetukalner - First of three planned Phase 3 MDD studies now initiated - Expanding ion channel portfolio includes Kv7 and Nav1.7 candidates ...
Xenon Pharmaceuticals ( XENE ) Up 2.4% Since Last Earnings Report: Can It Continue?
Xenon Pharmaceuticals (XENE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Xenon Showcases New Long-Term Azetukalner Data from X-TOLE OLE Study in FOS at AES 2024 - Xenon Pharmaceuticals ( NASDAQ:XENE )
- OLE data shows sustained monthly reduction in seizure frequency, impressive seizure freedom rates, and consistent AE safety profile suggesting long-term efficacy and tolerability of azetukalner - Approximately one in three patients on drug for at least 36 months achieved seizure freedom for a ...
Xenon Showcases New Long-Term Azetukalner Data from X-TOLE OLE Study in FOS at AES 2024
- OLE data shows sustained monthly reduction in seizure frequency, impressive seizure freedom rates, and consistent AE safety profile suggesting long-term efficacy and tolerability of ...
CERo Therapeutics, Inc. Appoints Chris Ehrlich CEO
SOUTH SAN FRANCISCO, Calif, Dec. 06, 2024 ( GLOBE NEWSWIRE ) -- CERo Therapeutics Holdings, Inc. ( Nasdaq: CERO ) ( "CERo" ) , an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics augmented with phagocytic mechanisms derived from the innate ...
Xenon to Showcase New Long-Term Azetukalner Data at AES 2024
VANCOUVER, British Columbia and BOSTON, Nov. 25, 2024 ( GLOBE NEWSWIRE ) -- Xenon Pharmaceuticals Inc. ( Nasdaq: XENE ) , a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced ...
Xenon to Showcase New Long-Term Azetukalner Data at AES 2024 - Xenon Pharmaceuticals ( NASDAQ:XENE )
Five posters to be presented including new long-term 36-month data from the ongoing X-TOLE OLE study of azetukalner in FOS and findings around mental health and comorbidity burdens of FOS New pre-clinical data from the Company's Nav1.1 program
Xenon Q3 Loss Narrower Than Expected, Pipeline Development in Focus
XENE reports a narrower-than-expected third-quarter 2024 loss. Its development programs for azetukalner in epilepsy and MDD are progressing well.
Longboard Set to be Acquired by Lundbeck for $2.6B, Stock Soars 52%
LBPH stock soars 52% on announcing that it is set to be acquired by Lundbeck for a total consideration of $2.6 billion to bolster the latter's neuro pipeline.
Intra-Cellular's Caplyta Sales Boost Revenues, Dependence a Woe
ITCI is seeing strong Caplyta sales, driven by a high prescription rate. However, its heavy reliance on the drug's sales for growth is concerning.
Xenon to Present at BofA Securities 2024 CNS Therapeutics Virtual Conference - Xenon Pharmaceuticals ( NASDAQ:XENE )
VANCOUVER, British Columbia and BOSTON, Oct. 02, 2024 ( GLOBE NEWSWIRE ) -- Xenon Pharmaceuticals Inc.
Xenon to Present at BofA Securities 2024 CNS Therapeutics Virtual Conference
VANCOUVER, British Columbia and BOSTON, Oct. 02, 2024 ( GLOBE NEWSWIRE ) -- Xenon Pharmaceuticals Inc. ( Nasdaq:XENE ) , a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced its ...
Xenon Showcases Azetukalner Data at 15th European Epilepsy Congress - Xenon Pharmaceuticals ( NASDAQ:XENE )
Three presentations highlighting long-term data and improved quality of life outcomes in adults with focal onset seizures VANCOUVER, British Columbia and BOSTON, Sept. 09, 2024 ( GLOBE NEWSWIRE ) -- Xenon Pharmaceuticals Inc.
Praxis Stock Up as Epilepsy Candidate Shows Reduction in Seizures
Shares of PRAX gains on positive efficacy data from the mid-stage study of its investigational candidate, relutrigine, for two epilepsy indications.
Xenon ( XENE ) Focuses on Neuro Candidate Amid Pipeline Woe
Xenon's (XENE) clinical studies of azetukalner in epilepsy and other neurological disorders are progressing well. However, any setback is set to hurt the stock in the absence of a deep pipeline.
Xenon Expands Leadership Team with Matthew D. Ronsheim, Ph.D. as Chief Operating Officer - Xenon Pharmaceuticals ( NASDAQ:XENE )
VANCOUVER, British Columbia and BOSTON, Aug. 12, 2024 ( GLOBE NEWSWIRE ) -- Xenon Pharmaceuticals Inc. XENE, a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced the appointment of ...
Xenon ( XENE ) Q2 Earnings Miss, Pipeline in Focus, Stock Down
Xenon (XENE) is down as it reports a wider-than-expected second-quarter 2024 loss. Its development programs for azetukalner in epilepsy and MDD are progressing well.
Longboard ( LBPH ) Up 14% as Epilepsy Drug Gets Breakthrough Tag
Longboard (LBPH) gains 14% as the FDA grants the Breakthrough Therapy designation to its investigational epilepsy treatment candidate, bexicaserin, for patients aged two years or older.
Meet 2024's rising stars of equity research, the up-and-comers helping investors separate the winners from the losers
Meet Business Insider's 2024 Rising Stars of Equity Research - Business Insider ...
Neurocrine Biosciences Announces CEO Succession Plan
Board of Directors appoints Kyle Gano, Ph.D., Chief Business Development and Strategy Officer, as CEO-elect, effective October 11, 2024 Kevin Gorman, Ph.D., to continue to serve on the Neurocrine Board of Directors
Xenon Pharmaceuticals Presents Data from Phase 2 X-NOVA Clinical Trial of Azetukalner in Major Depressive Disorder at the American Society of Clinical Psychopharmacology 2024 Annual Meeting
VANCOUVER, British Columbia, May 28, 2024 ( GLOBE NEWSWIRE ) -- Xenon Pharmaceuticals Inc. ( Nasdaq:XENE ) , a neuroscience-focused biopharmaceutical company, announced data presentations highlighting azetukalner ( XEN1101 ) clinical data in major depressive disorder ( MDD ) at the American ...
Acne Vulgaris Market to Register Sustainable Growth by 2034, Examines DelveInsight | Key Companies - Dermata Therapeutics, AstraZeneca, Novartis Pharmaceuticals, UCB Pharma, Incyte Corporation
Acne Vulgaris Market to Register Sustainable Growth by 2034, Examines DelveInsight | Key Companies - Dermata ... PR ...
Xenon ( XENE ) Q1 Earnings Beat Estimates, Pipeline in Focus
Xenon (XENE) reports better-than-expected first-quarter 2024 earnings. Its development programs for azetukalner in epilepsy and MDD are progressing well.
What Makes Xenon Pharmaceuticals ( XENE ) a New Buy Stock
Xenon Pharmaceuticals (XENE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Xenon Pharmaceuticals to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference - Xenon Pharmaceuticals ( NASDAQ:XENE )
VANCOUVER, British Columbia, April 10, 2024 ( GLOBE NEWSWIRE ) -- Xenon Pharmaceuticals Inc. XENE, a neurology-focused biopharmaceutical company, today announced that the company will present at the 2024 Bloom Burton & Co. Healthcare Investor Conference taking place April 16-17, 2024.
IBD Rating Upgrades: Xenon Pharmaceuticals Shows Improved Technical Strength
The Relative Strength ( RS ) Rating for Xenon Pharmaceuticals ( XENE ) jumped into a higher percentile Wednesday, as it got a lift from 69 to 75. X IBD's proprietary rating tracks market leadership with a 1 ( worst ) to 99 ( best ) score.
Xenon ( XENE ) Q4 Earnings Top Estimates, Pipeline in Focus
Xenon (XENE) reports mixed fourth-quarter 2023 financial results, wherein earnings beat estimates but revenues missed the same. Its development programs for XEN1101 in epilepsy and MDD are progressing well.
This Analyst Is Bullish On Biohaven's Approach in Neuro-Psych Space - Biohaven ( NYSE:BHVN )
RBC Capital Markets has initiated Biohaven Ltd BHVN, noting optimized development across programs. The analyst highlights the company's way of identifying promising technologies and targets and leveraging its management expertise to optimize the development path based on competitor data to become ...
Here's Why You Should Add Xenon ( XENE ) to Your Portfolio Now
Xenon's (XENE) late-stage studies in epilepsy are progressing well. The company is also gearing up to initiate a late-stage study for the MDD indication in 2024.
Wall Street Analysts Think Xenon Pharmaceuticals ( XENE ) Could Surge 25.76%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 25.8% in Xenon Pharmaceuticals (XENE). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the ...
Longboard Pharma ( LBPH ) Up on Upbeat Data From Epilepsy Study
Longboard Pharma (LBPH) skyrockets 316% on positive data from phase Ib/IIa study of bexicaserin for the treatment of seizures associated with a broad range of epilepsy indications.
Xenon Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
VANCOUVER, British Columbia, Jan. 03, 2024 ( GLOBE NEWSWIRE ) -- Xenon Pharmaceuticals Inc. ( Nasdaq:XENE ) , a neurology-focused biopharmaceutical company, today announced that the company will present at the 42nd Annual J.P. Morgan Healthcare Conference taking place in San Francisco, CA from ...
Xenon Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
VANCOUVER, British Columbia, Jan. 03, 2024 ( GLOBE NEWSWIRE ) -- Xenon Pharmaceuticals Inc. ( Nasdaq:XENE ) , a neurology-focused biopharmaceutical company, today announced that the company will present at the 42nd Annual J.P. Morgan Healthcare Conference taking place in San Francisco, CA from ...
Stocks To Watch: Xenon Pharmaceuticals Sees RS Rating Jump To 82
When looking for the best stocks to buy and watch, focus on those with rising relative price strength. One stock that fits that bill is Xenon Pharmaceuticals ( XENE ) , which had its Relative Strength ( RS ) Rating upgraded from 71 to 82 Tuesday.
Xenon Pharmaceuticals Getting Closer To Key Technical Measure
Xenon Pharmaceuticals ( XENE ) had its Relative Strength ( RS ) Rating upgraded from 69 to 74 Wednesday -- a welcome improvement, but still below the 80 or higher score you prefer to see. When you're researching the best stocks to buy and watch, be sure to pay attention to relative price ...
Xenon Pharmaceuticals Trying To Close In On Key Technical Measure
In a welcome move, Xenon Pharmaceuticals ( XENE ) saw its Relative Strength Rating improve from 63 to 71 on Friday. X When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength. IBD's unique rating identifies market leadership with a 1 ( worst ) ...
